CA Patent

CA3040815C — Anti-proliferative agents for treating pah

Assigned to Pfizer Inc · Expires 2021-07-20 · 5y expired

What this patent protects

Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6- acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1 -yl)pyridin-2yl]amino}pyrido[2,3- d]pyrimidin-7(8H)-…

USPTO Abstract

Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6- acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1 -yl)pyridin-2yl]amino}pyrido[2,3- d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3040815C
Jurisdiction
CA
Classification
—
Expires
2021-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.